LyGenesis Announces New Peer-Reviewed Publication Expanding Its Liver Regeneration Technology
PITTSBURGH, January 20, 2022 /PRNewswire/ — LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end-stage liver disease, type 1 diabetes, end-stage kidney disease, unique enzyme deficiencies and of aging, today announced the publication of a new peer-reviewed article published in a journal Hepatology about its organ regeneration technology.
LyGenesis’ technology is based on a broad base of preclinical studies in small and large animals showing that lymph nodes can serve as sites for organogenesis – the growth of functional ectopic organs. This latest publication, Fat-associated lymphoid clusters as expandable niches for ectopic liver development by Bing and colleagues published in Hepatology demonstrates that another lymphoid site, the fat-associated lymphoid cluster, may act as an additional anatomical location for ectopic liver development and restoration of liver function.
“This study consolidates and expands the use of lymphoid sites, including lymph nodes and fat-associated lymphoid clusters, for the development of functional ectopic livers. In this latest study, we were able to demonstrate the compensatory role of ectopic livers grown in fat-associated lymphoid clusters, which restored liver function and saved animals from otherwise fatal liver disease,” said Dr. Eric Lagasse, Scientific Director of LyGenesis, Associate Professor in the Department of Pathology and Fellow of the McGowan Institute for Regenerative Medicine in University of Pittsburgh.
dr. David Robin, CEO of Juvenescence Therapeutics, a lead investor in LyGenesis, said, “This latest peer-reviewed publication in one of the top journals in the field further supports LyGenesis’ platform technology using the lymph node and now other lymphoid sites as bioreactors to grow functionally, We are excited about the potential for patient impact as LyGenesis begins its first clinical trial in patients with end-stage liver disease.
Bing Han, Maria Giovanna Francipane, Amin Cheikhi, Joycelyne Johnson, Fei Chen, Ruoyu Chen and Eric Lagasse, Fat-associated lymphoid clusters as stretchable niches for ectopic liver development. Hepatology (2022). (https://doi.org/10.1002/hep.32277)
About LyGenesis, Inc.
LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functional ectopic organs. LyGenesis’ lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end-stage liver disease (ClinicalTrials.gov ID: NCT04496479). LyGenesis’ drug development pipeline includes cell therapies that can produce ectopic thymus (for aging and several other potential indications), pancreas (for type 1 diabetes) and kidney (for end-stage renal disease) . LyGenesis’ latest addition to its drug development pipeline focuses on orphan pediatric indications involving inborn errors of metabolism. Privately held with investment backing from Juvenescence, Longevity Vision Fund and other investors, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.